关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）2022 年年度报告已于 2023 年 4 月 1 日披露。为便于广大投资者进一步了解公司 2022 年经营情况，公 司定于 2023 年 4 月 20 日（星期四）下午 15:00-17:00 在全景网举行 2022 年年度 报告网上业绩说明会，本次年度报告网上业绩说明会将采用网络远程方式举行， 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度 业绩说明会或者直接进入公司路演厅（https://ir.p5w.net/c/002940.shtml）参与本 次年度业绩说明会。 出席本次年度网上业绩说明会的人员有：公司董事长方南平先生、总经理郑 国钢先生、财务总监毛松英女士、独立董事赵秀芳女士（如有特殊情况，参与人 员会有调整）。 为做好中小投资者保护工作，公司现就 2022 年度业绩说明会提前向投资者 征集相关问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,568,437,219.16, representing a 13.62% increase compared to ¥1,380,377,636.93 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥127,296,292.01, a 6.22% increase from ¥119,844,202.86 in 2021[20]. - The net profit after deducting non-recurring gains and losses was ¥120,346,889.82, up 11.58% from ¥107,857,508.30 in 2021[20]. - The total assets at the end of 2022 were ¥2,596,083,285.56, a 24.60% increase from ¥2,083,578,310.62 at the end of 2021[20]. - The net assets attributable to shareholders increased by 12.23% to ¥1,502,660,924.92 from ¥1,338,853,095.62 at the end of 2021[20]. - The basic earnings per share for 2022 was ¥0.93, reflecting a 6.90% increase from ¥0.87 in 2021[20]. - The company reported a total revenue of 10,433.70 million in 2022, representing a significant increase compared to the previous year[135]. Risk Management - The company emphasizes the importance of risk awareness regarding industry regulations, rising production costs, and potential talent loss in core technology[4]. - The company has outlined various risks in its management discussion, including the impact of centralized procurement and environmental policies on operations[4]. - The company faces risks from increased production costs due to stricter safety and environmental policies, which may impact overall profitability[105]. - The company is monitoring industry policy changes closely to mitigate risks associated with centralized procurement and price reductions that could affect its product performance[106]. - The company faces risks related to talent shortages and the potential loss of core technical personnel, which could impact operational efficiency[109]. - New drug development is subject to long cycles and various risks, including technical difficulties and market factors, which may delay progress or lead to project failures[110]. Research and Development - The company focuses on R&D as its core development driver, emphasizing the development of clinically valuable products in the competitive generic drug market[34]. - R&D expenses reached CNY 11,262.16 million, a significant increase of 114.30%, accounting for 7.18% of the operating revenue[45]. - The company is advancing multiple important generic drug projects, with several products having received drug registration certificates[62]. - The company aims to enhance its R&D capabilities by increasing investment and optimizing the structure of ongoing projects, with a focus on collaborative R&D and attracting high-end talent[97]. - The company plans to increase R&D investment in the near term, which may temporarily affect operational performance[110]. Corporate Governance - The company emphasizes strict compliance with environmental regulations, ensuring that emissions of waste gas, waste water, and waste residues meet the required standards[107]. - The company strictly adheres to the requirements of the Company Law and other regulations, ensuring a well-structured governance system and protecting the rights of shareholders, particularly minority shareholders[119]. - The company held shareholder meetings in compliance with legal requirements, ensuring equal participation and rights for all shareholders, with complete and transparent meeting records[120]. - The board of directors operates with a clear division of responsibilities, supported by four specialized committees, ensuring professional decision-making[121]. - The company maintains independence from its controlling shareholder in terms of business operations, assets, and financial management, ensuring no conflicts of interest[125]. Environmental Compliance - The company adheres to various environmental standards, including the Class III standard for surface water quality and the Class II standard for air quality[176]. - Wastewater treatment meets the Grade III standard of the "Comprehensive Discharge Standard for Wastewater" (GB8978-1996)[177]. - The company executes strict emission limits for air pollutants according to the "Pharmaceutical Industry Air Pollutants Emission Standards" (DB33/310005-2021)[178]. - The company has implemented noise control measures, adhering to the Class 3 standard for industrial areas, with daytime limits of 65dB and nighttime limits of 55dB[178]. - The company has established wastewater treatment facilities with a design capacity of 1000 tons per day, equipped with an online monitoring system for wastewater flow, pH, COD, and ammonia nitrogen[186]. Employee Engagement and Development - An employee stock ownership plan was launched in April 2022, with the first phase completed in November 2022, aimed at enhancing employee engagement and aligning interests[51]. - The company aims to establish a competitive compensation and benefits system to attract and retain talent, with annual evaluations for new graduates and various performance awards[160]. - The training strategy focuses on internal development supplemented by external recruitment, with programs for leadership, technical skills, and management training[161]. - The company is committed to building a professional lecturer team and internal course development to enhance employee skills and business quality[162]. Strategic Investments - The company is actively managing its subsidiaries and exploring potential mergers and acquisitions to drive growth[4]. - The company has made significant equity investments, including a total investment of ¥200,000,000 in Hunan New Harmony Biopharmaceutical Co., Ltd., acquiring a 10.61% stake[75]. - The company also invested ¥234,800,126.60 in Hunan Kory Biopharmaceutical Co., Ltd., obtaining a 23.48% share[75]. - The company plans to invest 200 million CNY in upgrading its manufacturing facilities to increase production efficiency by 30%[152]. Community Engagement - The company donated 1 million yuan to the Shenzhou Charity Association as part of its corporate social responsibility initiatives[200]. - The company contributed 500,000 yuan to the China Health Promotion Foundation to support public welfare in health promotion[200]. - The company actively participates in social welfare activities, including providing assistance to underprivileged families and donating electronic equipment to local schools[200].

证券代码：002940 证券简称：昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------|----------------------------|--------------|------------------|--------| | | | | | | | 投资者关 | □ 特定对象调研 □分析师会议 | | | | | | □ 媒体采访 □业绩说明会 | | | | | 系活动类 | □ 新闻发布会 □路演活动 | | | | | 别 | □ 现场参观 | | | | | | 其他（电话会议） | | | | | 参与单位 | 长江证券 | 方程嫣、刘浩 | 华夏久盈 | 胡攸乔 | | | 招商基金 | 钟赟 | 工银瑞信 | 李善欣 | | 名称及人 | 万家基金 | 王霄音 | 创金合信 | 皮劲松 | | 员姓名 | 神农投资 | 张薇 | 天弘基金 | 郭相博 | | | 国投瑞银 | 周思捷 | 国泰基金 | 林小聪 | | | 百年保险资管 | 陈兴 | 国联安 | 呼荣权 | | | 中信资管 | ...

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2020-003 | --- | --- | --- | |--------------|----------------------------|-----------------------------------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 动类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他（请文字说明其他活动内容） | | 参与单位名称 | 国海证券周超泽、徐晓欣 | | | 及人员姓名 | | | | 时间 | 2020 年 5 月 12 | 日下午 2:00 | | 地点 | 公司董事会办公室 | | | 上市公司接待 | | | | 人员姓名 | 副总经理、董事会秘书孙黎明 | | | 投资者关系活 | 一、介绍公司基本情况 | | | | | 公司主要从事的业务为医药生产制造业务，主要包括化学 | | 动主要内 ...

Group 1: Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. was established early and initially focused on raw materials before gradually shifting towards finished products [2] - The company is a leading manufacturer of alpha-keto acid raw materials in China and a core supplier for Fresenius Kabi [3] Group 2: Production and Market Insights - The company achieved sales of over 120 tons of alpha-keto acid raw materials in 2019, with over 90% of sales directed towards Fresenius Kabi [3] - The domestic market for compound alpha-keto acid tablets is relatively concentrated, with Fresenius Kabi holding approximately 70% of the hospital market share [3] Group 3: Sales and Export Strategy - The company primarily adopts a direct sales model for chemical raw materials, while finished products are sold through agents and third-party academic promotions [4] - In 2019, over 90% of the company's raw material sales were domestic, with a low export ratio due to the focus on supplying Fresenius Kabi [4] Group 4: Research and Development - The company aims to advance several new generic drugs with favorable competitive landscapes and fewer applications in the pipeline [5] - Key projects include the consistency evaluation of cefaclor sustained-release tablets and the development of new products such as compound alpha-keto acid tablets and others [5] Group 5: Regulatory and Market Challenges - The company is actively working on consistency evaluations to adapt to future procurement policies that will impact all generic drugs [5] - The progress of consistency evaluations for cefaclor sustained-release tablets indicates a temporary competitive advantage for the company [5]

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2020-004 | --- | --- | --- | |--------------|-------------------------------|----------------------------------| | | | | | | □ 特定对象调研 □分析师会议 | | | 投资者关系活 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | 其他（电话会议） | | | 参与单位名称 | 东吴证券研究所周新明、全铭 | 财通证券 李启明 | | | 广发证券 | 黄伟鑫 国海富兰克林基金 刘牧 | | 及人员姓名 | 国海证券 | 秦海燕 国联安基金 高兰君、呼荣权 | | | 华融证券 | 周艳曦 华润元大基金 廖星浩 | | | 辽宁成大 崔琦 磐厚动量 | 兰水 | | | 鹏华基金 郎超 | 平安银行 刘飞 | | | 浦银安盛基金 逞魏风 | 人保资管 蔡春根 | | | 融通基金 孙卫党 万吨资产 | 王海雨 ...

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2020-005 | --- | --- | --- | |--------------|----------------------------------|-------------------------------------------------| | | | | | 投资者关系活 | 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 动类别 | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称 | 五矿证券 | 梁良 中新融创 宋凡 | | 及人员姓名 | 久银投资 | 唐斌、赵谷蓉 财通资本 朱津鹏 | | | 偕沣资产 | 裴管铖 尚融资本 谢兴 | | | 萧山农商基金 | 盛江宏、王飞飞 通用投资 程偲 | | | 东方投行 | 王慧敏、唐诗云、孙宇 | | 时间 | 2020 年 9 月 11 日上午 | 11:00 | | 地点 | 公司二楼会议室 | | | 上市公司接待 ...

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2020-006 | --- | --- | --- | |--------------|----------------------------------|----------------------------------------------------| | | | | | 投资者关系活 | □ 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 动类别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | 其他（电话会议） | | | 参与单位名称 | | 高毅资产 冯鹏 上海宁泉资产管理 钱敏伟 | | 及人员姓名 | | 江苏瑞华 汤胜华 夏加荣 拾贝投资 褚培睿 | | | | 东方投行 王慧敏 王嘉乐 安东妮 欧阳志成 | | 时间 | 2020 年 9 月 14 日下午 | 4:00 | | 地点 | 电话会议 | | | 上市公司接待 | 副总经理、董事会秘书 孙黎明 | | | 人员姓名 | 证券事务助理 王燕红 | | | 投资者关 ...

证券代码：002940 证券简称： 昂利康 编号：2020-007 | --- | --- | --- | |--------------|----------------------------------------|-----------------------------------------------------| | | | | | 投资者关系活 | □ 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 动类别 | □ 新闻发布会 路演活动 | | | | □现场参观 | | | | □ 其他（电话会议） | | | 参与单位名称 | | 光大保德信基金 王振鹏 上海大正投资 张璟 | | | | 上海长风汇信股权投资基金 邱家茂 上海珩道投资 刘剑锋 | | 及人员姓名 | | 上海纯达资产 唐光英 上海铭深资产 高兵 | | | | 徐州博灏创业投资 祁超 中泰华信 庄凯 | | | | 偕沣资产 方骄华 裴管铖 山东铁路基金 张立波 | | | 磐厚资本 陈君 华泰保险 胡兰 | | | | 福信金控 陈凤玉 | | | | 东证投行 王慧敏 王嘉乐 蒋培 ...